Moderna ( (MRNA) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Moderna’s stock has recently taken a downturn after the company released its Q4 2024 earnings report, revealing a larger-than-expected net loss of $1.12 billion. This loss is largely due to a continued drop in demand for its COVID-19 vaccine, leading to a 66% fall in product sales compared to the previous year and a significant revenue decline. In response, Moderna is implementing cost-cutting measures, aiming to save $1 billion by 2025, and is pivoting its strategy to focus on launching new drugs, with several product approvals anticipated this year. Analysts have lowered their price targets, citing the weakened vaccine demand and uncertainties about future revenue from its respiratory vaccine products. Nonetheless, Moderna is determined to push forward with its late-stage pipeline, which is anticipated to propel long-term growth.
More about Moderna
YTD Price Performance: -24.00%
Average Trading Volume: 10,571,703
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $12.28B
For further insights into MRNA stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.